Skip to Content
Søg Menu

Promising Result for Patients with Prurigo Nodularis: Targeting IL-4 and IL-13 Signaling

Directly from EADV 2023, Martin Metz from Charité’s Institute of Allergology in Berlin, Germany, discusses the significance of dual inhibition of IL-13 and IL-4 in prurigo nodularis.
Martin Metz

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Bianca Maria Piraccini

Severe Alopecia Areata: JAK-Inhibitor Increases Hair Regrowth and Improve Quality of Life

/ Bianca Maria Piraccini
Alopecia areataEADV23 Play the Video 6:00
Marjolein de Bruin-Weller

Personalized Medicine on the Horizon for Atopic Dermatitis

/ Marjolein de Bruin-Weller
EADV23 Play the Video 3:19
Ida Vittrup

Risk Factors for JAK-Inhibitor Treatment in Atopic Dermatitis

/ Ida Vittrup
EADV23Atopisk dermatitis Play the Video 03:46
Stephan Weidinger

New Treatments for Atopic Dermatitis to Come

/ Stephan Weidinger
EADV23Atopisk dermatitis Play the Video 2:57
Lisa Schots

Concentration of Ixekizumab Paving the Way Towards Personalized Therapy in Psoriasis

/ Lisa Schots
EADV23Psoriasis Play the Video 1:37
Stephan Weidinger

New Insights Into Type 2 Inflammation in AD for Children and Adults

/ Stephan Weidinger
EADV23Type 2-inflammationAtopisk dermatitis Play the Video 2:00
Kim Papp

Deucravacitinib: Significantly Improved Symptoms and Signs of Psoriasis in Patients with Psoriasis

/ Kim Papp
EADV23Psoriasis Play the Video 02:52
Enikö Sonkoly

New Oral Drug Sotyktu for Plaque Psoriasis Patients Demonstrates Promising Results with Favorable Safety Profile

/ Enikö Sonkoly
EADV23Psoriasis Play the Video 3:38
Stephan Weidinger

AD: New Knowledge About Type 2 Inflammation and Skin Barrier Deficiency for Children and Adults

/ Stephan Weidinger
EADV23Type 2-inflammationAtopisk dermatitis Play the Video 4:52
Back to top